These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27059424)

  • 1. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.
    Borradori L; Sutton B; Shayesteh P; Daniels GA
    Br J Dermatol; 2016 Dec; 175(6):1382-1386. PubMed ID: 27059424
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
    Winkler JK; Schneiderbauer R; Bender C; Sedlaczek O; Fröhling S; Penzel R; Enk A; Hassel JC
    Br J Dermatol; 2017 Feb; 176(2):498-502. PubMed ID: 27061826
    [No Abstract]   [Full Text] [Related]  

  • 3. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
    Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
    JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete response of a locally advanced basosquamous carcinoma with vismodegib treatment.
    Sahuquillo-Torralba A; Llavador-Ros M; Caballero-Daroqui J; Botella-Estrada R
    Indian J Dermatol Venereol Leprol; 2019; 85(5):549-552. PubMed ID: 31389370
    [No Abstract]   [Full Text] [Related]  

  • 5. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
    Tran DC; Colevas AD; Chang AL
    JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
    [No Abstract]   [Full Text] [Related]  

  • 6. Expanding the Reach of Anti-PD-1 Therapy.
    Cancer Discov; 2015 Jul; 5(7):684-5. PubMed ID: 26034052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
    Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
    Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
    Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
    J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.
    Zalaudek I; Corneli P; Vernoni S; Fedele D; Papa G; Conforti C; Retrosi C; Vezzoni R; Fagotti S; Longone M; Farinazzo E; di Meo N; Pizzichetta MA
    Dermatol Ther; 2019 Nov; 32(6):e13107. PubMed ID: 31595596
    [No Abstract]   [Full Text] [Related]  

  • 11. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia : a case series and literature review.
    Eglmeier J; Debus D; Schultz ES
    Eur J Dermatol; 2020 Feb; 30(1):69-71. PubMed ID: 32250263
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and histological resolution of invasive squamous cell carcinoma by topical imiquimod 3.75%: a case report.
    Dirschka T; Schmitz L; Bartha Á
    Eur J Dermatol; 2016 Aug; 26(4):408-9. PubMed ID: 27097553
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
    Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
    [No Abstract]   [Full Text] [Related]  

  • 14. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma.
    Baltaci M; Fritsch P; Weber F; Tzankov A; Sögner P; Derler AM; Höpfl R
    Br J Dermatol; 2005 Jul; 153(1):234-6. PubMed ID: 16029373
    [No Abstract]   [Full Text] [Related]  

  • 16. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical chemotherapy of advanced cutaneous malignancy with 5-Fluorouracil creme.
    Litwin MS; Ryan RF; Reed RJ; Krementz ET
    J Surg Oncol; 1971; 3(3):351-65. PubMed ID: 5110339
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma.
    Pezeshki S; Hemmati S; Rezaei N
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):819-822. PubMed ID: 32852235
    [No Abstract]   [Full Text] [Related]  

  • 19. Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate.
    Parekh V; Gangadhar T; Kreider KL; Elenitsas R; Chu EY
    JAMA Dermatol; 2017 Jul; 153(7):719-721. PubMed ID: 28445579
    [No Abstract]   [Full Text] [Related]  

  • 20. Proceedings: Use of 5 fluorouracil in the topical therapy of skin cancer: a review of 157 patients.
    Litwin MS; Ryan RF; Ichinose H; Reed RR; Kremetz ET
    Proc Natl Cancer Conf; 1972; 7():549-61. PubMed ID: 4764922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.